阿帕替尼联合替吉奥治疗晚期胃癌患者的疗效及对预后的影响

doi:2022001750

摘要/Abstract

摘要：

目的　分析阿帕替尼联合替吉奥治疗晚期胃癌患者的临床效果，观察该联合用药方案对炎性因子、辅助型T细胞1（T helper 1 cell，Th1）和辅助型T细胞2（T helper 2 cell，Th2）类细胞因子水平的影响。方法　选取聊城市第二人民医院消化内科自2019年3月至2020年2月收治的晚期胃癌88例，采取随机数字表法分为对照组与观察组，各44例。对照组中男24例，女20例，年龄（65.25±2.42）岁，给予替吉奥治疗；观察组中男25例，女19例，年龄为（65.33±2.35）岁，在对照组基础上加用阿帕替尼行联合治疗。计数资料采用χ²检验，计量资料采取t检验，对比两组临床疗效、治疗前后血清肿瘤标志物水平、Th1和Th2细胞因子水平、不良反应以及生存情况。结果　对照组疾病控制率（DCR）为59.09%（26/44），观察组DCR为79.55%（35/44），差异有统计学意义（χ²=4.328，P=0.037）。治疗后，对照组癌相关糖类抗原（CA）19-9、癌胚抗原（CEA）及肿瘤特异生长因子（TSGF）水平分别为（9.20±4.23）U/ml、（2.53±0.41）μg/L、（61.75±14.25）U/ml，观察组CA19-9、CEA及TSGF水平分别为（4.98±2.87）U/ml、（1.96±0.39）μg/L、（53.20±16.37）U/ml，两组比较，差异均有统计学意义（t=5.476、6.682、2.613，均P<0.05）。治疗后，对照组γ-干扰素（INF-γ）、肿瘤坏死因子-α（TNF-α）、白细胞介素（IL）-4和IL-10水平分别为（9.83±1.68）μg/L、（4.98±0.83）pg/ml、（5.62±1.58）μg/L、（12.83±2.41）μg/L，观察组分别为（12.45±1.65）μg/L、（6.12±1.47）pg/ml、（3.18±1.17）μg/L、（8.76±2.11）μg/L，差异均有统计学意义（t=7.380、4.479、8.232、8.428，均P<0.05）。对照组中位进展时间、中位生存期分别为（7.23±1.31）个月、（5.10±1.39）个月，观察组分别为（5.31±0.75）个月、（9.33±2.54）个月，差异均有统计学意义（t=8.437、9.691，均P<0.05）。结论　阿帕替尼联合替吉奥治疗晚期胃癌患者可有效改善患者的临床症状及体征，改善血清肿瘤标志物、Th1和Th2细胞因子水平，生存情况更好，同时在治疗期间并不会增加不良反应，安全性较高。

关键词: 阿帕替尼, 替吉奥, 晚期胃癌, 疗效, 肿瘤标志物, Th1和Th2细胞因子水平, 生存率

Abstract: Objective　To analyze the clinical effect of apatinib combined with tegafur in the treatment of patients with advanced gastric cancer, and to observe the effect of the combination regimen on the levels of inflammatory factors and the cytokines of T helper 1 cells (Th1) and T helper 2 cells (Th2). Methods　Eighty-eight patients with advanced gastric cancer who were admitted to Department of Gastroenterology, Liaocheng Second People's Hospital from March 2019 to February 2020 was selected for the study. They were divided into a control group and an observation group by the random number table method, with 44 cases in each group. There were 24 males and 20 females in the control group; they were (65.25±2.42) years old; they were treated with tegafur. There were 25 males and 19 females in the observation group; they were (65.33±2.35) years old; they were treated with tegafur and apatinib. χ² test was used for the enumeration data, and t test for the measurement data. The clinical efficacies, serum tumor marker levels before and after the treatment, Th1 and Th2 cytokine levels, adverse reactions, and survival were compared between the two groups. Results　The disease control rate (DCR) was 59.09% (26/44) in the control group, and was 79.55% (35/44) the observation group, with a statistical difference (χ²=4.328, P=0.037). The levels of cancer-associated carbohydrate antigen (CA19-9), carcinoembryonic antigen (CEA), and tumor-specific growth factor (TSGF) after the treatment were (9.20±4.23) U/ml, (2.53±0.41) μg/L, and (61.75±14.25) U/ml in the control group, and were (4.98±2.87) U/ml, (1.96±0.39) μg/L, and (53.20±16.37) U/ml in the observation group, with statistical differences between these two groups (t=5.476, 6.682, and 2.613; all P<0.05). After the treatment, the levels of interferon-γ (INF-γ), tumour necrosis factor-α (TNF-α), interleukin (IL)-4, and IL-10 were (9.83±1.68) μg/L, (4.98±0.83) pg/ml, (5.62±1.58) μg/L, and (12.83±2.41) μg/L in the control group, and were (12.45±1.65) μg/L, (6.12±1.47) pg/ml, (3.18±1.17) μg/L, and (8.76±2.11) μg/L in the observation group, with statistical differences between these two groups (t=7.380, 4.479, 8.232, and 8.428; all P<0.05). The median progression time and survival time were (7.23±1.31) months and (5.10±1.39) months in the control group, and were (5.31±0.75) months and (9.33±2.54) months in the observation group, with statistical differences (t=8.437 and 9.691; both P<0.05). Conclusion　Apatinib combined with tegafur in the treatment of patients with advanced gastric cancer can effectively improve their clinical symptoms and signs, the levels of serum tumor markers, and Th1 and Th2 cytokines, and does not increase the incidence of adverse reactions, and the patients have better survival.

Key words: Apatinib, Tegafur, Advanced gastric cancer, Curative effect, Tumor markers, Th1 and Th2 cytokine levels, Survival rate

齐有涛　王东梅　白玉焕　孔令甲　敬长春　计蓓. 阿帕替尼联合替吉奥治疗晚期胃癌患者的疗效及对预后的影响[J]. 国际医药卫生导报, 2022, 28(13): 1815-1819.

Qi Youtao, Wang Dongmei, Bai Yuhuan, Kong Lingjia, Jing Changchun, Ji Bei. Apatinib combined with tegafur in treatment of patients with advanced gastric cancer and its influence on prognosis[J]. International Medicine and Health Guidance News, 2022, 28(13): 1815-1819.

参考文献

[1] 程霞.消瘤汤联合FOLFOX6化疗方案对进展期胃癌患者术后血清VEGF水平及生存率的影响[J].河南医学研究,2019,28(19):3566-3567.DOI:10.3969/j.issn.1004- 437X. 2019.19.052.
[2] 朱洁品,娄金书.生长抑素联合多西他赛和替吉奥治疗进展期胃癌的临床研究[J].现代药物与临床,2017,32(1):124-128.DOI:10.7501/j.issn.1674-5515.2017.01.030.
[3] 中华人民共和国国家卫生健康委员会.胃癌诊疗规范(2018年版)[J/CD].肿瘤综合治疗电子杂志,2019,5(1):55-82.DOI:10.12151/JMCM.2019.01-08.
[4] 鲍云华,李俭杰.介绍新的实体瘤治疗反应评价标准(RECIST)[J].中国肺癌杂志,2005,8(1):77-78.
[5] 王惠枫,沈静,张甜甜.消癌平片联合常规化疗对胃癌患者血清TGF-α、VEGF水平的影响[J].海南医学,2020,31(2):181-183.DOI:10.3969/j.issn.1003-6350.2020.02.013.
[6] 叶飒,王飞燕,周宏斌,等.非小细胞肺癌患者血清IL-17、VEGF水平与临床分期和预后的相关性研究[J].浙江医学,2018,40(6):573-576.DOI:10.12056/j.issn.1006-2785. 2017.40.6.2017-2377.
[7] 施育鹏,潘妍.新辅助化疗对进展期胃癌患者血清VEGF、肿瘤标志物水平的影响[J].临床医学研究与实践,2019,4(17):7-9.DOI:10.19347/j.cnki.2096-1413.201917004.
[8] 郎丰平,赵毓毅,范鹏.甲磺酸阿帕替尼治疗晚期胃癌的疗效及安全性分析[J].实用癌症杂志,2017,32(6):996-998.DOI:10.3969/j.issn.1001-5930.2017.06.037.
[9] 高金平,韩涛,朴瑛,等.阿帕替尼联合替吉奥治疗老年或瘦弱患者晚期胃癌临床研究[J].临床军医杂志,2017,45(1):9-12.DOI:10.16680/j.1671-3826.2017.01.03.
[10] 王新国,祁玉娟,阚捷,等.沙利度胺联合一线化疗方案治疗胃癌krukenberg瘤血清VEGF水平变化与疗效相关性研究[J].中国煤炭工业医学杂志,2018,21(4):406-410.DOI:10.11723/mtgyyx1007-9564201804016.
[11] 黄毅超,刘云军,何宛谦,等.阿帕替尼与替吉奥联合治疗晚期胃癌疗效分析及对相关细胞因子的影响[J].中国中西医结合消化杂志,2018,26(3):252-255.DOI:10.3969/j.issn. 1671-038X.2018.03.07.
[12] 杨颖,夏曙,何肇晴,等.血清CA125、Cyfra21-1和VEGF水平在非小细胞肺癌患者放化疗敏感性和预后评估中的应用价值[J].实用癌症杂志,2019,34(6):940-943.DOI:10.3969/j.issn.1001-5930.2019.06.020.
[13] 艾良,张麒.阿帕替尼联合替吉奥二线治疗胃癌患者对CA19-9、CEA、TSGF水平的影响[J].实用癌症杂志,2018,33(4):541-543.DOI:10.3969/j.issn.1001-5930. 2018.04.006.
[14] 马靓,赵霞,钱琦,等.阿帕替尼联合替吉奥治疗晚期胃癌的疗效观察[J].肿瘤药学,2018,8(2):174-178.DOI:10.3969/j.issn.2095-1264.2018.02.10.
[15] 郭军,刘登湘,王娜,等.阿帕替尼联合替吉奥二线治疗70例晚期胃癌[J].肿瘤学杂志,2019,25(9):841-843.DOI:10.11735/j.issn.1671-170X.2019.09.B016.
[16] 宋尧波.阿帕替尼治疗中晚期胃癌的疗效及预后影响因素分析[J].国际医药卫生导报,2020,26(8):1046-1048.DOI:10.3760/cma.j.issn.1007-1245.2020.08.003.
[17] 郑中显,潘明.阿帕替尼联合替吉奥用于初始治疗失败后晚期肝癌的疗效及安全性分析[J].蚌埠医学院学报,2020,45(7):917-920.DOI:10.13898/j.cnki.issn.1000-2020. 07.020.
[18] 朱建军,吴剑,徐磊荣.阿帕替尼联合替吉奥治疗复发转移食管癌的疗效及对患者QLQ-30评分的影响[J].临床与病理杂志,2021,41(12):2830-2835.DOI:10.3978/j.issn. 2095-6959.2021.12.013.
[19] 黄志荣,曹齐生,杜成荣,等.甲磺酸阿帕替尼联合化疗在晚期胃癌中临床研究[J].临床和实验医学杂志,2020,(22):2407-2410.DOI:10.3969/j.issn.1671-4695.2020.22.016.
[20] 蔡明志,王学军,刘勇,等.以替吉奥为基础联合阿帕替尼的三药方案在不可切除晚期胃癌转化治疗中的应用[J].中华胃肠外科杂志,2021,24(2):179-184.DOI:10.3760/cma.j.cn.441530-20201101-00582.
[21] 张子博,刘羽,李勇,等.阿帕替尼联合其他药物治疗进展期及晚期胃癌的研究进展[J].河北医药,2021,43(7):1082-1086.DOI:10.3969/j.issn.1002-7386.2021.07.029.
[22] 杨牡丹,高峻,刘晓玲,等.甲磺酸阿帕替尼联合多西他赛二线治疗晚期胃癌的临床研究[J].中华肿瘤杂志,2020,42(7):594-597.DOI:10.3760/cma.j.cn112152-20190121-00027.
[23] 宋爱华,王育生.替吉奥联合甲磺酸阿帕替尼治疗晚期胃腺癌效果Meta分析[J].肿瘤研究与临床,2021,33(5):368-372.DOI:10.3760/cma.j.cn115355-20200722-00402.
[24] 叶再生,曾奕,魏晟宏,等.阿帕替尼联合奥沙利铂和替吉奥在胃癌腹膜转移转化治疗中的安全性及近期疗效观察[J].中华胃肠外科杂志,2021,24(3):240-247.DOI:10.3760/cma.j.cn.441530-20200530-00326.
[25] 李磊,王韬,曾俊琳,等.伊立替康联合阿帕替尼治疗术后转移性胃癌患者临床疗效和安全性分析[J].现代生物医学进展,2021,21(12):2293-2297.DOI:10.13241/j.cnki.pmb. 2021.12.021.
[26] 蔡清,徐金发,章秀芳,等.阿帕替尼联合替吉奥二线治疗Ⅲ～Ⅳ期胃癌近期疗效及对血清CEA和CA19-9水平的影响[J].临床与病理杂志,2020,40(8):1955-1960.DOI:10. 3978/j.issn.2095-6959.2020.08.005.
[27] 张斌忠,董来荣,何春华,等.阿帕替尼联合替吉奥化疗对照SOX方案一线治疗晚期胃癌的临床研究[J].外科理论与实践,2020,25(4):341-343.DOI:10.16139/j.1007-9610. 2020.04.015.
[28] 刘敏,张洽,凌丰宇,等.阿帕替尼联合替吉奥治疗晚期胃癌的疗效及安全性的Meta分析[J].现代肿瘤医学,2020,28(17):3009-3015.DOI:10.3969/j.issn.1672-4992. 2020.17.020.
[29] 郭军,王娜,刘登湘,等.甲磺酸阿帕替尼片联合替吉奥和奥沙利铂治疗晚期胃癌的效果与安全性[J].中国医药,2020,15(4):577-579.DOI:10.3760/j.issn.1673-4777.2020.0 4.023.
[30] 曹永峰,肖金章,王晓丽,等.阿帕替尼联合替吉奥治疗化疗失败晚期胃癌患者临床疗效[J].临床军医杂志,2020,48(12):1462-1463,1466.DOI:10.16680/j.1671-3826. 2020.12.26.